Clinical trials: Psychological Disorder
Schizophrenia
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia
- Trial name
- NCT05326347
- Testing
- OPC-34712FUM/ Brexpiprazole fumarate
- Where
- Japan
- Volunteers
- 247 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with…
- Trial name
- NCT02203838
- Testing
- RBP-7000
- Where
- 48 sites in United States
- Volunteers
- 500 people
- Sponsor
- Indivior Inc.
Insomnia
Evaluation of Digital Sleep Program to Improve Sleep Among New Parents
Sleep disturbances are highly prevalent during the postpartum period, with an estimated 40-60% of new parents experiencing inadequate sleep.
- Trial name
- NCT07302893
- Testing
- Digital CBT-I
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Udisense DBA Nanit
Schizophrenia
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013).
- Trial name
- NCT05211947
- Testing
- Iclepertin
- Where
- 303 sites in United States, Argentina and 38 more
- Volunteers
- 1,356 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Mild to Moderate Sleep Disorder, Pressure
Research on Sleep and Emotion Testing of Tea Theanine Casein Hydrolysate Pressed Candy
The study evaluates the improvement of sleep, emotion, and skin by standardizing the use of the blend (Tea Theanine Casein Hydrolysate Pressed Candy, whose active ingredients include Tea Theanine, Casein Hydrolysate, and Saffron…
- Trial name
- NCT07207252
- Testing
- Tea Theanine Casein Hydrolysate Pressed Candy, Pressed Candy
- Where
- China
- Volunteers
- 171 people
- Sponsor
- ChinaNorm
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Alzheimer Disease
A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
To test that LY450139, a gamma-secretase inhibitor, will reduce the rate of newly synthesize Amyloid Beta by determining the amount of newly synthesized 13C6 leucine-labeled Amyloid Beta in lumbar cerebrospinal fluid from…
- Trial name
- NCT00765115
- Testing
- LY450139
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02450890
- Where
- 4 sites in Taiwan
- Volunteers
- 114 people
- Sponsor
- Orient Pharma Co., Ltd.
Attention-Deficit / Hyperactivity Disorder
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01357993
- Testing
- JNS001
- Where
- 29 sites in Japan
- Volunteers
- 253 people
- Sponsor
- Janssen Pharmaceutical K.K.
Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate
PGx Medication Safety Reviews of Persons With IDD
The purpose of this study is to assess the feasibility of a comprehensive medication review and PGx initiative as part of the care process for individuals in the care of CP Unlimited.
- Conditions
- Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate, Developmental Disability
- Trial name
- NCT07092852
- Testing
- Cheek swab for PGx testing, Medication safety review
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- GalenusRx, Inc.
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Attention Deficit Hyperactivity Disorder
Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)
Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.
- Trial name
- NCT01472991
- Testing
- TC-5619-238 5mg, TC-5619-238 25mg
- Where
- 14 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Bipolar Disorder, Depression, Bipolar
Adjunctive Ziprasidone in the Treatment of Bipolar I Depression
The purpose of this study is to determine if a treatment regimen of ziprasidone plus a mood stabilizer is safe and effective in the short term treatment of Bipolar I Depression.
- Trial name
- NCT00483548
- Testing
- Ziprasidone
- Where
- 70 sites in United States, Australia and 1 more
- Volunteers
- 298 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Metabolic Syndrome, Anxiety
PRebiotic Intervention for Metabolic and MEntal Health (PRIME)
The purpose of the study is to determine whether a daily prebiotic fibre blend can reduce systemic inflammation, dyslipidemia, and self-report measures of mental health in individuals with metabolic syndrome.
- Conditions
- Metabolic Syndrome, Anxiety, Mood, Stress
- Trial name
- PRIME (NCT06216626)
- Testing
- myota's prebiotic fibre blend
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Myota GmbH
Alzheimer's Disease, Dementia
Nutritional Programme for Dementia Elderly Patient
The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.
- Trial name
- NCT00479843
- Testing
- Nutritional programme
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Société des Produits Nestlé (SPN)
Progressive Cognitive Decline
Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.
- Trial name
- NCT01400425
- Testing
- florbetapir F 18
- Where
- 18 sites in United States
- Volunteers
- 239 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Disorder
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder.
- Trial name
- NCT00107926
- Testing
- Licarbazepine
- Where
- 44 sites in United States, Austria and 11 more
- Volunteers
- 343 people
- Sponsor
- Novartis Pharmaceuticals